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AbstrACt
Objective To explore the views of UK-based recipients of 
Morita Therapy (MT) on the acceptability of MT.
Design Qualitative study nested within a pilot randomised 
controlled trial of MT (a Japanese psychological therapy 
largely unknown in the UK) versus treatment as usual, 
using post-treatment semistructured interviews analysed 
with a framework approach.
setting and participants Participants who received 
MT as part of the Morita Trial, recruited for the trial from 
General Practice record searches in Devon, UK. Data from 
16 participants were purposively sampled for analysis.
results We identified five themes which, together, 
form a model of how different participants viewed and 
experienced MT. Overall, MT was perceived as acceptable 
by many participants who emphasised the value of the 
approach, often in comparison to other treatments they 
had tried. These participants highlighted how accepting 
and allowing difficulties as natural phenomena and shifting 
attention from symptoms to external factors had facilitated 
symptom reduction and a sense of empowerment. We 
found that how participants understood and related to the 
principles of MT, in light of their expectations of treatment, 
was significantly tied to the extent to which MT was 
perceived as acceptable. Our findings also highlighted 
the distinction between MT in principle and practice, 
with participants noting challenges of engaging with the 
process of therapy such as fear and discomfort around 
rest, needing sufficient support from the therapist and 
others, and the commitment of treatment.
Conclusions People in the UK can accept the premise 
of MT, and consider the approach beneficial and novel. 
Therefore, proceeding to a large-scale trial of MT is 
appropriate with minor modifications to our clinical 
protocol. Participants’ expectations and understandings 
of treatment play a key role in acceptability, and future 
research may investigate these potential moderators of 
acceptability in MT.
trial registration numberC ISRCTN17544090; Pre-
results.
IntrODuCtIOn AnD ObjeCtIves
Depression and generalised anxiety disorder 
(GAD) are the two most common mental 
health disorders: lifetime prevalence is esti-
mated at 16.2% and 5.7% for depression 
and GAD, respectively.1–3 Depression is the 
leading cause of disability worldwide and 
is often chronic, recurrent, comorbid with 
other conditions and associated with a high 
risk of suicide.2 4–7 Between 2011 and 2030, 
the effect of depression on global economic 
output is predicted to be US$5.36 trillion.8 
Medication and cognitive behavioural therapy 
(CBT) have the strongest evidence-base for 
treating these conditions.9 10 However, many 
people are resistant to such interventions, 
with between one-third and half of patients 
not responding to treatment.11–20 Thus, there 
is a scope to test new potentially effective 
treatments.
Morita Therapy (MT) is a Japanese psycho-
therapy developed by Dr Shōma Morita in 
1919 and informed by Zen Buddhist prin-
ciples.21 22 Key components are outlined in 
table 1. It is a holistic approach aiming to 
improve everyday functioning rather than 
targeting specific symptoms.23 Through 
conceptualising unpleasant emotions as 
part of the natural ecology of human experi-
ence, MT seeks to re-orientate patients in the 
natural world and potentiate their natural 
healing capacity.21 Morita therapists thus 
help patients to move away from symptom 
strengths and limitations of this study
 ► This is the first study to explore the views of UK-
based patients about Morita Therapy (MT).
 ► The use of qualitative methods generated rich in-
sights into participants’ views of MT, informing the 
development of a model of how different partici-
pants engaged with and experienced the approach.
 ► Our sample size was constrained by the number of 
Morita Trial participants meeting our sampling crite-
ria. However, our purposive and theoretically driven 
sampling framework enabled us to explore both the 
breadth and depth of data, and identify issues with 
acceptability in particular.
 ► The analysis may not have readily reflected how 
participants’ views changed over time and some 
challenges were encountered in establishing how 
acceptability was shaped by other factors and/or 
vice versa.
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preoccupation and combat, which are considered to exac-
erbate symptoms and interfere with this natural recovery 
process.24 By helping patients to accept symptoms as 
natural phenomena which ebb and flow as a matter of 
course, MT is in sharp contrast to the focus of established 
Western approaches on symptom control.25 Thus, MT has 
potential to provide UK patients with a distinct alterna-
tive to current National Institute For Health And Clinical 
Excellence (NICE)-recommended treatment options.
The Morita Trial, a mixed methods feasibility study 
guided by a pragmatic philosophy26 and encompassing 
a pilot randomised controlled trial and embedded qual-
itative interviews, was the first trial of MT in the UK. 
The trial received ethical approval from the National 
Research Ethics Service South West—Frenchay (refer-
ence 15/SW/0103). In all, 68 participants with major 
depressive disorder, with or without anxiety disorder(s), 
were recruited through General Practice record searches 
in Devon, UK and randomised to receive treatment as 
usual (TAU) or TAU plus 8–12 sessions of MT delivered 
by trained therapists at the University of Exeter’s AccEPT 
clinic following the UK MT outpatient protocol devel-
oped by the study team.27 The trial established that a 
large-scale MT trial is feasible with minor modifications 
to the pilot trial protocol, and that MT shows promise 
in treating depression. The protocol (see online supple-
mentary file 1) and quantitative results are reported else-
where.28 29
Here, we report the results of the embedded qualitative 
study designed to address the clinical uncertainties30 asso-
ciated with a large-scale trial. As the acceptability of MT 
in the UK was unknown, gathering data on this was essen-
tial to inform any necessary amendments to our clinical 
protocol and ensure that the treatment administered in 
any large-scale trial is acceptable. Thus, our research ques-
tion was as follows: How acceptable is MT to participants?
MethODs
Design
In-depth semistructured interviews with participants 
who received MT within the Morita Trial, as part of a 
mixed methods embedded design.31 For the quantitative 
(reported elsewhere29) and qualitative components, we 
collected data concurrently and analysed data sequen-
tially (with quantitative data informing our sampling of 
qualitative interviews for analysis: see below).
Table 1 Key components of MT
Components Definition
Natural world MT conceptualises unpleasant thoughts and emotions as part of the natural ecology of the human 
experience. It draws on the natural world, and the place of humans within it, to emphasise that 
symptoms are not subject to the patient’s control, and will naturally ebb and flow with time.
Acceptance and 
allowance of internal 
states/vicious cycle
All emotions and thoughts (internal states) are accepted as they are. Any attempts to control, resist, 
avoid or intervene in symptoms are considered to exacerbate them within a vicious cycle; therapists 
thus help patients to move away from symptom preoccupation and combat and towards acceptance 
and a focus on action-taking. Thus, the objectives of therapy are to shift attention and perspective, 
and move patients to a position of accepting and responding to phenomenological reality as it is, 
rather than controlling or ‘fixing’ symptoms.
Normalisation Therapists label thoughts and emotions as ‘unpleasant’ and ‘pleasant’ but not ‘good’ or ‘bad’. They 
emphasise that all emotions are natural, or normal, and will ebb and flow on their own so long as 
attempts are not made to resist them.
Fumon (inattention to 
symptoms)
Therapists, in an effort to shift patients’ attention away from symptom preoccupation and combat, 
will not focus on discussion or analysis of patients’ symptoms or their causes, but will ‘steer’ the 
conversation towards action-taking and the external environment.
Diaries Patients complete daily diaries on which therapists provide comments which facilitate an acceptance 
of internal states and refocus attention on action-taking and the external environment.
Four-phased model Rest and action-taking are structured within four phases: (1) rest; (2) light repetitive activities; (3) 
more challenging activities and (4) social reintegration. The process is understood to aid experiential 
acceptance of the natural ebb and flow of thoughts and emotions, to re-orientate patients in nature, 
and to refocus attention from the ‘self’/internal states to external reality.
Rest MT seeks to potentiate patients’ natural healing capacities, in contrast to resisting and exacerbating 
symptoms. Patients sit with their thoughts and emotions as they are, to learn how they naturally ebb 
and flow with time if left unattended and to build a natural desire to take action.
Action-taking with 
symptoms
Patients learn to undertake purposeful and necessary action, with or without their symptoms; action 
which is driven by ‘desire for life’ rather than undertaken for the purpose of feeling differently. MT thus 
aims to improve everyday functioning in spite of symptoms, with symptoms reducing as a by-product 
of moving from a mood-oriented to purpose-oriented and action-based lifestyle.
MT, Morita Therapy.
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recruitment and data collection
At baseline, we asked participants whether they would 
be willing to be interviewed about their experiences of 
therapy. On therapy completion, we invited consenting 
participants allocated to MT (n=34) to interview, 
conducted at University of Exeter premises or the partici-
pant’s home, depending on participant preference.
We developed a semistructured topic guide (table 2) 
based on recent mental health trials addressing similar 
questions,19 32 33 MT literature and our MT optimisation 
study findings.27 Topics included participants’ thoughts 
and feelings before treatment, understandings and experi-
ences of treatment, barriers to treatment and mechanisms 
of change, which were initially explored using open-ended 
questions defining these areas34 (table 2: topic of discus-
sion). While our topic guide thus helped to ensure consis-
tency in data collection and allow for comparison across 
participants, interviews were interactive, responsive and 
flexible in order to pursue unanticipated views and the 
most salient details for each participant34 35: individual 
responses were probed to investigate participants’ mean-
ings, enabling both the exploration of participants’ views 
on pre-defined topics of interest and the elicitation of 
participants’ own themes.36 The probe areas included in 
our topic guide (table 2) thus served as an aide-memoire 
for the interviewer to ensure discussion of each element 
of interest, and informed follow-up questions which were 
asked in a flexible manner dependent on the informa-
tion already provided by the interviewee.34 37 Following 
the first three interviews, we amended the topic guide to 
include probe areas based on the views already elicited.
With participants’ permission, interviews were audio-re-
corded and transcribed verbatim. Transcripts were 
checked for accuracy. We made field notes during each 
interview and summarised these at interview completion, 
which helped inform topic guide amendments, facili-
tated sampling and were referred to alongside transcripts 
during analysis.
Table 2 Topic guide
Topic of discussion Probe areas
Thoughts and feelings before treatment
Can you tell me a bit about what led you to take part in this 
trial?
 ► Anything about MT in particular
 ► Why are they involved in this trial in particular
 ► What did they expect from treatment
 ► Any problems with which they particularly wanted help
Understanding/experiences of treatment
Having now attended MT, please can you describe to me your 
understanding of what MT is?
Please tell me about your experiences of receiving treatment
 ► Understanding of the goals of MT
 ► What it felt like receiving treatment
 ► Anything in particular that they liked or found helpful
 ► Anything they did not like or found less helpful
 ► How could the treatment have been improved
 ► How well the therapy helped them with the problems they 
wanted to work on
 ► To what extent did therapy match their expectations—why 
(not)/how (not)/in what ways
 ► Length of therapy sessions/total length of treatment/way in 
which therapy was ended
 ► Each phase of therapy
 ► Diary and written comments
 ► Style of the therapist
 ► Concept of ‘desire for life’
 ► Concept of the vicious cycle
 ► Idea of accepting the natural ebb and flow of emotions
 ► Connection to natural world
 ► Use of metaphors
 ► Amount of explanation and rationale provided
Barriers to treatment
We are interested in reasons why people might decide to 
attend some or all of their therapy sessions. Please could you 
tell me about your reasons for deciding to continue with or 
stop therapy?
 ► Personal contextual factors
 ► Specific therapy factors
 ► Therapeutic relationship factors
 ► Anything (else) that could have been done to overcome 
these difficulties
Active treatment components/mechanisms
We are interested in the ways in which treatment may have 
brought about changes for you, particularly in terms of 
anything you may have learnt from the treatment. Please can 
you tell me about any changes that happened for you during 
treatment?
 ► Anything they learnt during treatment
 ► What was it about treatment which brought about any 
changes
 ► What impact did such changes have for them
MT, Morita Therapy. 
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sampling
Using a nested sampling design, we analysed data from a 
subsample of interviews.38 39 This approach enabled us to 
purposively select ‘key informants’ [38 p.240] on accept-
ability according to theoretically driven criteria deemed 
important in answering our research question.39 40 These 
criteria were as follows: (1) treatment adherence, given 
the potential for this to be related to views of therapy; 
(2) whether participants demonstrated a response to 
treatment (ie, Patient Health Questionnaire 941 score <10 
at follow-up), given the potential for participants’ views 
to be confounded by their degree of symptom improve-
ment. Our objective was to include a quota of three partic-
ipants within each subgroup in the resulting sampling 
matrix (table 3).39 We therefore selected participants in 
order to achieve maximum variation according to these 
criteria, and aimed to both capture the breadth of views 
on acceptability and explore the depth and diversity of 
views within each subgroup.35 40 42 For participants who 
both completed and responded to treatment, we further 
purposively sampled data according to additional criteria 
deemed potentially relevant: presence or not of GAD at 
baseline; participants’ experience or not of CBT; partici-
pants’ gender; therapist.
In determining the sample size, we prioritised the 
study purpose in order to achieve sampling adequacy: we 
estimated the number of participants required to suffi-
ciently answer the research question by achieving both 
breadth and depth of information.35 42–45 This estimation 
was informed by the concept of data saturation46–48 and 
related findings49 which suggested that an analysis of 12 
interviews could provide a thorough picture of partici-
pants’ views. The final sample size was informed by the 
heterogeneity of the population, the number of selection 
criteria and the number of participants meeting these 
criteria.35
Analysis
We analysed data in NVivo1050 using Framework anal-
ysis35 to allow for an abductive approach. We achieved 
familiarisation with the data through reading transcripts, 
and following the guidance of Miles, Huberman and 
Saldana39 completed first cycle coding and developed an 
initial thematic framework as batches of transcripts were 
analysed, iteratively combining the topic guide and the 
overall impression of the narratives in context. Using 
this framework, we completed second cycle coding on 
individual transcripts and analysed them thematically 
using a constant comparison approach.39 51 We charted 
data in analytic/framework matrices, as per the Frame-
work approach,35 to allow within and across case analyses 
and the exploration of relationships between themes; 
throughout this process, we interpreted data with the 
aid of thematic maps to make sense of participants’ 
perspectives, understand and structure the relationships 
between themes, and conceptualise the overall picture 
of participants’ views.35 52–54 We explored negative cases 
and provided explanations of variance,55 ensuring all 
observations relevant to the research question were incor-
porated. Two authors (HVRS and JF) conducted data 
analysis, each coding raw data (HVRS all data; JF a subset) 
and meeting regularly to develop themes and discuss data 
interpretation.
Patient involvement
The Morita Trial follows on from an iterative programme 
of work conducted to develop our MT clinical protocol, 
whereby we optimised MT according to the views of 
potential patients and therapists.27 The patient mate-
rials were developed on the basis of consultation with a 
Public and Patient Involvement (PPI) expert and similar 
materials used in other mental health trials which had 
received feedback from PPI groups (eg, PenPIG http:// 
clahrc- peninsula. nihr. ac. uk/). A former trial participant, 
who expressed an interest in supporting our research and 
will be involved in the further dissemination of results, 
has co-written a summary sheet explaining our results in 
lay terms which has been sent to consenting former trial 
participants.
results
From November 2015 to January 2017, one author 
(HVRS) completed 28 interviews with MT participants 
lasting between 24 and 93 min. We did not interview six 
participants because they could not be contacted (n=3; 
8.8%); declined (n=2; 5.9%) or had moved away (n=1; 
2.9%). We sampled 16 interviews for analysis (table 3): 
these included all participants who did not complete 
and/or did not respond to treatment (n=10) and six who 
completed and responded to treatment. Thus, only addi-
tional participants who both completed and responded 
to treatment were not sampled for analysis. Participant 
characteristics are provided in table 4.
Participants’ views were understood within five 
themes: (1) the impact of incompatible expectations 
and understandings; (2) identifying with the princi-
ples of MT: receptivity and relevance; (3) approaching 
Table 3 Sampling matrix
Adherence to treatment
Withdrew <5 sessions Withdrew ≥5 sessions Completed treatment
Treatment response?
(follow-up PatientHealth 
Questionnaire 9 score <10)
Yes n=3 n=1 n=6
No n=2 n=3 n=1
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and understanding MT as a process; (4) facilitating the 
process: (overcoming) challenges and barriers and (5) 
the value and impact of MT. Each theme encompassed a 
number of constituent themes (figure 1). These themes 
were developed to explore and explain the relationships 
between the constituent themes and the acceptability 
of MT, within a model of how MT was experienced by 
different participants.
During analysis, it was clear that participants’ views 
comprised different categories which linked to accept-
ability. Particularly salient was the sense that participants’ 
expectations and understandings either facilitated or 
hindered their engagement with MT. To capture this, 
the first three themes essentially convey different typol-
ogies of participants’ approaches towards and experi-
ences of treatment: theme 1 contrasts themes 2 and 
3, with participants’ accounts generally falling within 
either theme 1 or themes 2 and 3. Thus, participants who 
brought expectations of treatment which were incon-
sistent with MT generally misunderstood the approach 
and considered it to be unacceptable (theme 1), with 
a failure to either identify with the MT principles or 
understand treatment as a process to progress through. 
In contrast, those whose prior expectations and experi-
ences facilitated their identification with the MT prin-
ciples (theme 2) typically engaged with the approach 
from the offset, with their overwhelmingly positive 
experiences of treatment tied to their understanding 
of MT as a process (theme 3) and leading to positive 
accounts of the value and impact of MT (theme 5).
Theme 4 describes the difficulties participants expe-
rienced engaging with therapy on a practical rather 
than conceptual level. While whether such difficul-
ties amounted to barriers to continuing treatment 
was often moderated by themes 1–3 (participants with 
incompatible expectations and understandings of 
treatment were less likely to tolerate such difficulties), 
this theme also captures how for some participants the 
principles of MT may be acceptable (ie, they identify 
with the principles as per theme 2) while the process 
of treatment is not. Thus, the relationship between 
this theme and the preceding themes highlights a key 
thread throughout participants’ accounts and this 
model of MT: the distinction between MT in prin-
ciple and practice. Overall, while an ability to identify 
with the principles manifested as highly important in 
seemingly priming participants for MT, the challenges 
of translating these principles into a process which is 
feasible to engage with (as per theme 4) further shaped 
acceptability.
Figure 1 illustrates the relationships between themes 
and how these shape an overall picture of engagement 
with, and acceptability and impact of, MT. This model 
is not intended to provide a representative account of 
acceptability across the themes: theme 1, in which the 
most negative views are described, is dedicated to the 
accounts of a minority of participants who discontinued 
treatment and were purposively sampled to explore any 
issues with acceptability.
Participants’ trial ID numbers are included in brackets 
after quotes.
Table 4 Participant characteristics
Characteristic
n (%) unless 
otherwise stated
Total n=16
Gender
  Female 9 (56)
Age (years)
  Mean (SD) 48 (12)
Ethic origin
  White British 16 (100)
Education
  No qualifications 1 (6)
  GCSE or O Level 3 (19)
  Post-GCSE or O Level 4 (25)
  Undergraduate degree 4 (25)
  Postgraduate qualification or higher 4 (25)
Marital status
  Married or cohabiting 10 (63)
Number of children
  Mean (SD) 1 (1)
PHQ-9 (depression) score
  Mean (SD) at baseline 17 (5)
  Mean (SD) at follow-up 9 (7)
  Follow-up PHQ-9 score <10 10 (63)
Adherence to Morita Therapy
  Number of sessions attended (mean (SD)) 7 (4)
  Completed treatment 7 (44)
  Withdrew ≥5 sessions 4 (25)
  Withdrew <5 sessions 5 (31)
Morita therapist (of two available)
  Therapist 01 8 (50)
Secondary SCID diagnoses (at baseline)
  Any anxiety disorder 10 (63)
  Generalised anxiety disorder 7 (44)
  Panic disorder with agoraphobia 4 (25)
  Panic disorder without agoraphobia 4 (25)
  Social phobia 2 (13)
  Post-traumatic stress disorder 1 (6)
  Obsessive compulsive disorder 1 (6)
Previous psychotherapy/counselling (at least one 
course of)
  Any psychotherapy (not including counselling) 12 (75)
  Cognitive behavioural therapy 10 (63)
  Mindfulness-based cognitive therapy 4 (25)
  Eye movement desensitisation and reprocessing 1 (6)
  Other psychotherapy 4 (25)
  Counselling 8 (50)
Percentages may not always total 100 due to rounding.
GCSE, General Certificate of Secondary Education;  PHQ-9, Patient Health 
Questionnaire 9; SCID, Structured Clinical Interview for DSM-V.
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theme 1: the impact of incompatible expectations and 
understandings
Some participants demonstrated discrepancies between 
MT and their expectations of treatment; expectations 
which focused on seeking a solution for symptoms 
(constituent theme (a)) or exploring and expressing 
the self (constituent theme (b)). Participants also indi-
cated how such expectations can feed the construction of 
rationales for treatment components which are inconsis-
tent with MT (constituent theme (c)). As such, MT fails 
to achieve its assigned purpose, and/or fails to provide 
participants with the approach they seek. This theme 
contrasts with others: participants’ accounts typically fall 
either within theme 1 or themes 2, 3 and 5.
(a)Seeking a solution for symptoms
Several participants expressed a desire for therapy to 
provide a cure, answers or techniques to remove symp-
toms. Accordingly, participants resisted the underlying 
premise of MT to allow both pleasant and unpleasant 
internal states as natural and inevitable: their goal was 
to eliminate the unpleasant. These participants typi-
cally appeared to view the therapist as a holder of expert 
knowledge and abilities: someone who should ‘fix’ them 
or impart powerful techniques, with a sense of handing 
responsibility for both improvement and understanding 
therapy over to the therapist.
It’s like a computer; you would replace the chip, why 
can’t you do it in your head? It would just make you 
feel better… Why can’t I be happy all the time instead 
of having one day good, one bad! (MT28)
(b)Exploring and expressing the self
Several participants expressed hopes that treatment 
would provide in-depth exploration, analysis and discus-
sion of their difficulties.
I was hoping it was like a situation where I could open 
myself up… analysing why, you know, how I’m feel-
ing…or why you feel bad. (MT61)
These expectations shaped views of MT, particularly 
Fumon (therapists’ inattention to symptoms), with a 
sense that this somewhat stifled participants’ self-expres-
sion and desire for someone to talk to and understand 
them. Thus, participants seeking a more exploratory and 
analytical approach felt somewhat ‘shut down’ (MT54) by 
and disappointed in MT.
(c)Failing at the wrong job: the substitution of rationale
For participants whose accounts fall within the constit-
uent themes above, their expectations often shaped 
misunderstandings of the purpose of MT. In particular, 
participants typically substituted the rationale for rest 
(which is, primarily, to experience the natural ebb and 
Figure 1 Thematic map.
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flow of internal states) with one more consistent with their 
preconceptions. For example, a participant who sought 
a cure considered rest unable to help them ‘conquer’ 
their depression (MT51). Others considered rest an 
opportunity to have a relaxing ‘break’ from symptoms. 
Alternatively, a participant whose expectations focused 
on in-depth self-analysis, potentially on ‘an unconscious 
level’, had the following recollections of rest:
They said that we were gonna analyse your sleeping 
thing and arrange for you to sleep for a certain time… 
Actually planning something like that was really like, 
well, ‘this isn’t gonna work’. (MT61)
Thus, participants were assigning a MT incongruent 
purpose to rest; the achievement of which rest was not 
intended or able to fulfil. In turn, participants expressed 
a sense of both themselves and the therapy having ‘failed’ 
(MT19).
theme 2: Identifying with the principles of Mt: receptivity and 
relevance
In contrast to theme 1, many participants described 
approaching MT with insights, experiences and expec-
tations which facilitated their identification with the MT 
principles, such as the underlying premise of accepting 
unpleasant thoughts and emotions (constituent theme 
(a)) and/or particular treatment components (constit-
uent theme (b)).
(a)Readiness to accept
In recalling what appealed to them about MT before 
treatment, many participants expressed a sense of readi-
ness to accept symptoms as part of oneself and life:
What attracted me was…it was a way of getting back 
to nature and realising that it’s a part of you and part 
of the human experience, and stop catastrophising 
everything. (MT63)
This ‘readiness to accept’ appeared to be facilitated by 
participants’ prior experiences of and insights into the 
nature of their difficulties: participants expressed under-
standings that symptoms could not be cured, they natu-
rally come and go, and attempts to control them could 
worsen them. Thus, Moritian concepts of the ‘vicious 
cycle’ and the natural ebb and flow of internal states 
resonated strongly for such participants. These under-
standings were often shaped by previous treatment expe-
rience, typically CBT and counselling, which participants 
felt were too ‘focused on your past and trying to stop you 
having these thoughts and feelings’ (MT50) with poten-
tial to ‘feed into’ the vicious cycle.
[Morita Therapy] reinforced what I’d already hooked 
onto as a major problem for me… [CBT] was sort of 
feeding my need to fix myself… I came away from 
CBT going ‘I’ve got to stop thinking these things, I’ve 
got to think differently’ and you don’t have that kind 
of control over your thoughts, I don’t think. (MT45)
(b)Attraction to the features of MT
There was a sense from many participants that specific 
elements of MT ‘grabbed’ them from the offset and 
encouraged them to engage with the approach. Different 
features manifested as salient for different participants. 
Often, participants were attracted to ‘the use of the 
natural world’ (MT43), valuing both understanding 
human nature in relation to the natural world and a more 
literal engagement with nature. For others, key features 
included the focus on action-taking, understanding diffi-
culties as reflections of underlying desires and working 
with the ‘authentic self’.
The thought of somebody nurturing you and slow-
ly trying to find what things you’re looking for and 
what your values are and what little things you can go 
and do that are true to your authentic self… That’s 
what I’ve been looking for, for the last twenty years! 
(MT50)
theme 3: approaching and understanding Mt as a process
Many participants understood the MT components as a 
part of a naturally unfolding progressive journey (constit-
uent theme (a)) providing accumulative opportunities 
for learning and re-focusing attention (constituent theme 
(b)) and for owning responsibility for change (constit-
uent theme (c)), as opposed to attempting to isolate 
each component as a potential technique for overcoming 
symptoms (as per theme 1).
(a)Allowing a natural progression
Many participants described MT as providing a natural 
and gentle progression. Within this, participants conveyed 
a sense of helpful balance in the process: the four-phased 
structure and therapist guidance were coupled with an 
individualised pace and lack of directive instructions. 
This enabled participants to gradually ‘build up’ (MT16) 
themselves, their confidence and activity levels through 
achievable ‘bite-sized’ steps (MT43).
It was just this brilliant, gradual process, it sort of – the 
first stage broke me down, and then it was re-building 
me. (MT55)
Some participants also suggested that the purpose of 
treatment naturally unfolded through engagement with 
it, and highlighted the importance of MT as an experien-
tial, rather than purely intellectual, process.
I’ve been allowed to discover it, guided gently and 
then I had to discover it for myself. And I think if 
you find it for yourself, and aren’t following lots of 
instructions, it’s almost like nature teaches you… It’s 
kind of hit me at a bit of a visceral level. (MT63)
(b)Methods for transition and learning
Many participants spoke of MT in terms of providing 
accumulative opportunities for learning about human 
nature and transitioning from engagement in the vicious 
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cycle to an acceptance of symptoms and external focus of 
attention. Key to this was the incorporation of methods, 
such as rest, diaries and natural-world metaphors, for 
learning about the transient nature of emotions.
Being with your thoughts and then learning that 
thoughts come and go… You relate it to different sea-
sons of the year, and storms come, but they pass, and 
the sea goes calm and all of those sorts of things, you 
realise that happens with you naturally as a human 
being. (MT50)
Participants also spoke of the phases and diaries as a 
means of highlighting and enabling action-taking, and of 
Fumon (therapists’ inattention to symptoms) as valuable 
for reducing the vicious cycle.
What was good about what [therapist] was doing was 
they would go ‘Stop’ as soon as I started that conver-
sation, ‘You’re now scratching the itch’, you know, 
‘Your mind wants to fix it and we’re gonna sit here 
and fix it for half an hour, and fixing it’s the prob-
lem, right?’… I did go away from – after a couple of 
sessions, thinking ‘What they’re actually saying is I’m 
just wasting my time’. (MT45)
In contrast to theme 1, these participants did not judge 
the treatment components in terms of how successful they 
were as tools for managing symptoms, but how successful 
they were as methods for learning and transition. This 
accurate understanding of the purpose of MT appeared 
crucial to participants’ willingness to tolerate challenging 
components (such as rest), and how successful partici-
pants considered therapy to be.
(c)Ownership of responsibility: making you think
Many participants described the value of MT, particularly 
therapists’ diary comments, partially in terms of ‘making 
them think’. There was a welcome sense that, rather than 
the therapist providing answers and imparting knowl-
edge, they provided subtle cues which encouraged partic-
ipants to take responsibility for their own learning and 
application of the MT principles.
With the use of the diary, it’s just picking out the sa-
lient points that are making you think… Instead of 
saying ‘you need to do this’… [My therapist] was al-
lowing me to pick up on very subtle signals, so - in 
trying to do that for myself. (MT33)
Through this, participants spoke of their therapist facil-
itating a re-evaluation of themselves and their lives, and 
equipping them to proceed post-treatment with a sense 
of self-efficacy: a desire to ‘walk on my own with Morita in 
mind’ (MT63).
theme 4: Facilitating the process: (overcoming) challenges 
and barriers
Participants described some challenges concerning the 
more practical rather than conceptual elements of MT, 
including fear and discomfort (constituent theme (a)), 
needing support from others (constituent theme (b)), 
needing sufficient therapist guidance (constituent theme 
(c)) and the commitment of treatment (constituent 
theme (d)). This highlights a distinction throughout 
participants’ accounts between identification with the 
MT principles and the feasibility of engaging with the MT 
process itself.
(a)Fear and discomfort
Participants described fear and discomfort they had 
experienced at times during therapy, predominantly in 
relation to rest. This typically connected to participants 
having avoided their thoughts and feelings for some time. 
Whether or not the challenges of rest were acceptable to 
participants, or developed into barriers to continuing 
therapy, was linked to participants’ expectations and 
understandings of treatment: those who assigned incor-
rect purposes to rest (as per theme 1) were disinclined 
to tolerate it; those who understood rest as a means of 
learning (as per theme 3) tended to persevere with it, 
acknowledging its importance.
[Therapist] said ‘Just go with it, let it all come out’, 
‘cos before I tried my hardest to block it off. After 
9 days I thought ‘Oh heck!’… But yeah, as I say, it 
worked. It wasn’t pleasant but when I got to the end 
of it I could see we’d done it…‘cos I learned that 
you can get through it and come out the other side. 
(MT55)
(b)Safety and support from others
Participants spoke of the need to feel safe, supported 
and encouraged by their significant others during 
therapy, with some describing a lack of support from 
others as a major factor in their decision to discon-
tinue therapy. For one participant, their lack of 
personal safety and support led them to discontinue 
therapy despite their eagerness to continue, indi-
cating the importance of creating a safe space for rest 
and the need for a certain degree of stability in partic-
ipants’ lives to facilitate engagement with MT:
Because of my neighbour who was being threatening 
and harassing, I didn’t feel safe to sit in that environ-
ment… and my Mum started drinking terribly bad-
ly, so that all got so bad I just thought ‘I need to do 
something quickly with my life’. (MT50)
With this requirement for safety and support mani-
festing particularly in relation to rest, several participants 
indicated that including their partner in the therapy 
session in which rest was explained helped to meet this 
need.
(c)Providing guidance and reassurance
Participants recalled some discomfort with a lack of 
clear instruction and sufficient reassurance being 
given around treatment components, particularly 
diaries.
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One thing I struggled with was having just a blank 
canvas in the diary… I found it quite hard to under-
stand exactly what was needed. (MT16)
Participants indicated that providing a more detailed 
‘framework’ (MT17) for diary completion and assuring 
participants that there is no ‘correct’ way of doing this 
were potential ways of minimising such challenges. In the 
context of therapy sessions feeling somewhat intensive 
and information rich, participants also suggested that 
providing audio-recordings and handouts, and ensuring 
regular input from participants during sessions, could 
facilitate their engagement with MT.
(d)Burden and commitment
There was a sense from participants that MT required 
a large commitment. Some participants had difficulties 
attending treatment sessions, or struggled to find time 
for components such as rest and diary writing. For several 
participants, this time commitment among work and 
caring responsibilities were key factors in their decision to 
discontinue therapy. For participants with incompatible 
expectations and understandings of treatment (theme 1), 
the requirements of MT also at times created a sense of 
burden.
It was pressurising me into doing it, every day you had 
to remember certain things… Then more and more, 
every week there’s a bit more added and that’s when 
it became too much. (MT28)
In the absence of understanding MT as a process along-
side the failure of treatment components to achieve their 
assigned (incorrect) purpose (such as reducing symp-
toms), these participants appeared to consider these 
components as somewhat devoid of meaning and simply 
extra things which they ‘had to do’, creating a sense of 
pressure to ‘perform’ (MT19) for a therapy which was not 
working for them.
theme 5: the value and impact of Mt
Many participants, excluding those whose accounts fell 
within theme 1, described the value and impact of MT in 
terms of providing a preferable alternative to other ther-
apies (constituent theme (a)), the value of acceptance 
(constituent theme (b)), transformation from dwelling to 
doing (constituent theme (c)), empowerment and liber-
ation (constituent theme (d)) and effect on symptoms 
(constituent theme (e)).
(a)A preferable alternative
Participants often described MT as preferable to (mind-
fulness-based) CBT and counselling, typically contrasting 
the accepting and allowing stance of MT with the 
controlling and combative stance of CBT. Participants 
welcomed a move from ‘thinking positively’ towards 
‘accepting that not everything is positive’ (MT43) and 
considered the naturalisation of unpleasant experiences 
‘less judgemental and conflicting’ than CBT (MT17). 
While participants viewed MT as a ‘philosophy to take you 
through life’ (MT50) in which patients are ‘not seen as 
a bunch of symptoms’ (MT15), they described (mindful-
ness-based) CBT as a ‘tool-kit’ approach/‘sticking plaster’ 
(MT43) or ‘short-term fix’ (MT63) in comparison. There 
was thus a sense that MT was a more ‘holistic’ (MT43), 
pervasive and potentially sustainable approach, which 
had made fundamental and instinctive changes to their 
perspective.
I have done other work in the past but this seems 
to have struck a chord of change within, not just a 
‘Right, this is a strategy’… That never, ever worked 
for me. It’s something fundamentally, I hope, I feel 
very optimistic, has changed with my acceptance of 
these feelings. (MT63)
(b)Relinquishing control: the value of acceptance
The impact of MT often centred on participants’ accep-
tance and allowance of both pleasant and unpleasant 
experiences, and a sense of relinquishing attempts to 
control the uncontrollable. Critical to this was how 
therapy had normalised unpleasant emotions, making 
them permissible and demonstrating that it is ‘okay to 
be with’ them (MT33). Often, participants extended this 
attitude of acceptance more broadly in terms of ‘what will 
be will be’ (MT33) and ‘it’s just how it is’ (MT43) with 
regards to all aspects of life they felt unable to control.
I don’t worry about things, not anymore… [Therapist] 
has taught me to let things go, there’s nothing you 
can do to change anything, if it’s going to happen it 
will happen, you’ve just got to go with it and take the 
rough with the smooth… realising that has helped 
me. (MT37)
More widely, participants noted the positive impact 
of the acceptance, normalisation and permissibility of 
difficulties on their self-image and relationships, noting 
decreases in shame and criticism of both self and others.
(c)Transformation: from dwelling to doing
Participants described shifts in their attention and 
behaviour from fixating on symptoms towards focusing 
outwardly on the external environment: ‘you’re doing 
things rather than just dwelling on them’ (MT43). Accord-
ingly, participants often described paying less attention to 
(fixing) symptoms, being ‘more present’ in the moment 
(MT43) and ‘getting more involved’ (MT33) with others, 
activity, nature and life.
It’s about moving your focus away from what’s going 
on inside to carrying on what’s going on in the real 
world… my mind is completely outside of myself, I’m 
looking forward and I’m interested in what I’m doing 
and I’m taking full part in it, and to be honest I don’t 
even think about anxiety. (MT45)
There was thus a sense of transition from partici-
pants’ lives being dictated by their symptoms to being 
dictated by external factors, with action-taking now being 
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motivated by the action itself rather than a desire to over-
come symptoms.
(d)Empowerment and liberation
Running through participants’ accounts of acceptance 
and transition was a sense of empowerment through 
freedom from former restrictions, fears, judgements and 
struggles. Participants indicated that they were no longer 
‘scared’ of their symptoms (MT15/MT50) and that relin-
quishing attempts to ‘fix’ them induced a sense of relief 
and liberation of energy.
I accept that it’s almost, um, honestly being able to 
stop trying to cure yourself and just, yeah, give up 
that struggle… It’s a feeling of – a little bit of relief. 
(MT45)
Participants also felt empowered to take action through 
learning that they can do so with symptoms and, as such, 
felt able to tackle avoided activities such as driving and 
changing jobs. This empowerment was often expressed 
in terms of increased self-confidence, feeling better 
equipped to dictate and manage situations, and feeling 
‘a lot more in control’ (MT16) in terms of increased 
autonomy over their lives. This appeared to have mani-
fested through a redirection of efforts and altered owner-
ship of responsibility: through accepting what cannot be 
controlled (internal states) and focusing on what can be 
controlled (behaviour).
(e)Improvement in symptoms and mood
When questioned as to whether MT had helped them 
with their difficulties, participants often stated ‘a lot’, 
and described improvements such as stopping antide-
pressant medication. However, participants’ spontaneous 
accounts typically focused on their changed outlooks 
and behaviours, prioritising the adoption of MT princi-
ples, with symptom reduction considered secondary to 
this or described through the lens of acceptance. While 
many referred to (an acceptance of) some continued 
symptoms, they typically noted these were of reduced 
duration due to reductions in the vicious cycle and 
increased action-taking. Similarly, participants described 
more frequent pleasant experiences, and more thorough 
engagement with and enjoyment of these, given this time 
was no longer spent attempting to analyse and pre-empt 
unpleasant experiences.
My anxiety’s gone, my depression’s gone and I’m in a 
much better place. I had a bad little patch…but then 
a day later I was absolutely fine, so instead of being 
stuck in that cycle for weeks, it was only like a couple 
of days. (MT50)
DIsCussIOn
This paper presents a model of how different partici-
pants viewed and experienced MT, highlighting three 
key findings. First, the link between acceptability and 
participants’ expectations, understandings and recep-
tivity to the MT principles was demonstrated, suggesting 
some participants may find MT too discordant with their 
treatment expectations to be acceptable. Thus, the first 
three themes capture different typologies whereby partic-
ipants who held expectations and understandings of 
treatment which are incompatible with MT (theme 1), 
such as seeking a cure for symptoms, were contrasted with 
those who identify with the principles (theme 2), such 
as accepting the natural ebb and flow of internal states, 
and accurately understand the purpose of the treatment 
components as part of a progressive process (theme 3).
Second, the distinction between MT in principle and 
practice was highlighted: while the centrality of identifi-
cation with MT on a conceptual level was stressed, the 
challenges of engaging with MT on a practical level also 
shaped acceptability (theme 4). These challenges centred 
on fear and discomfort around rest, and other practical 
factors which are relevant in many forms of psycholog-
ical therapy56 57 such as needing safety and support from 
others, needing sufficient therapist guidance and reas-
surance, and the required commitment. Whether partic-
ipants were willing to tolerate such challenges was often 
shaped by the degree to which they identified with the 
MT principles and understood the purpose of the treat-
ment components.
Finally, MT was perceived as acceptable by many partic-
ipants, who emphasised the value and impact of the 
approach (theme 5) in terms of the acceptance, normal-
isation and permissibility of difficulties; a sense of trans-
formation from life being dictated by symptoms to being 
dictated by external factors; empowerment and liberation 
from former restrictions, fears, judgements and strug-
gles; and decreases in symptoms as a by-product of such 
changes. For these participants, MT was often described 
as preferable to other treatments they had tried.
strengths and limitations
This study is the first to explore the views of UK-based 
patients about MT. Our use of qualitative methods enabled 
us to develop a rich account of acceptability within a 
model of how MT was experienced and understood by 
different participants, incorporating both exploratory 
and explanatory insights.
Our sample size was constrained by the number of 
Morita Trial participants meeting our sampling criteria. 
Nonetheless, it was possible to explore the views of partic-
ipants who, together, fulfilled all manifestations of our 
sampling criteria, and only additional participants who 
both completed and responded to treatment were not 
sampled for analysis. Purposively (and explicitly) selecting 
participants to achieve maximum variation along theo-
retically driven dimensions allowed us to explore the 
breadth of views, obtain key insights in relation to issues 
with acceptability and conduct in-depth (non-superfi-
cial) analysis which represents the views of all of those 
sampled.58 As analysis continued to the point at which 
no new themes were emerging and both the breadth and 
 o
n
 30 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023873 on 29 May 2019. Downloaded from 
11Sugg HVR, et al. BMJ Open 2019;9:e023873. doi:10.1136/bmjopen-2018-023873
Open access
depth of data were explored, we consider data saturation 
and sampling adequacy to have been achieved.44 49
We recognise potential limitations of this study. The 
analysis may not have readily reflected how participants’ 
views changed over time; for some factors deemed 
important in acceptability, such as identifying with the 
principles, the reliance on post-treatment interviews 
posed some challenges: it was difficult to ascertain the 
extent to which such identification had been held early 
in treatment (as claimed by many participants) and thus 
shaped views on acceptability versus the extent to which 
it emerged from participants’ engagement in treatment. 
Therefore, in the future, it may be informative to capture 
the views and values of participants before as well as after 
treatment, to assess the nature of this relationship in 
more depth.
Furthermore, although our sample was diverse in terms 
of age and gender, the distribution of the education levels 
is higher than that found in the general UK population.59 
Although the education distribution broadly reflects that 
of our whole pilot trial sample,29 those MT participants 
with whom we could not conduct an interview (n=6) had 
a lower distribution of education level than those in our 
sample. It is possible therefore that our results are not 
transferable to the UK population as a whole, and more-
over that education level may impact on the perceived 
acceptability of MT: the approach may be more attractive 
to and/or more suitable for those of a higher education 
level. Therefore, in a large-scale trial, it will be important 
to measure education level as a potential moderator of 
response and acceptability in MT.
Implications and future research
Our findings indicate that MT was acceptable to, and 
beneficial for, many participants. In the context of our 
promising pilot trial data on treatment adherence and 
outcomes (reported elsewhere), we suggest that the 
views of a minority of participants who found MT less 
acceptable should not prevent us from proceeding to 
a large-scale trial of MT using the UK Morita Therapy 
outpatient protocol. However, our results do suggest 
that some minor modifications to our clinical protocol 
may enhance acceptability. In particular, the provision of 
increased therapist explanation and reassurance around 
diary completion may ease some of the discomfort partic-
ipants described in relation to this. Other suggestions 
made by participants, such as providing handouts during 
therapy, may also be incorporated.
One key finding is the link between acceptability and 
participants’ identification with the MT principles in 
light of their expectations and understandings of treat-
ment. This may inform further amendments to our 
clinical protocol in an effort to both better manage 
participants’ expectations and better explain the 
purpose of the treatment components (eg, re-terming 
‘rest’, which has connotations of ‘relaxation’, as ‘being 
with’ may clarify its purpose). This finding is also consis-
tent with previous research which highlights the role of 
patients’ expectations of and preferences for treatment 
in moderating treatment acceptability, engagement and 
response,60–63 and is an early indication of who MT may 
be more or less acceptable to. Our mixed methods study, 
reported elsewhere, extends these findings by relating 
them to treatment adherence and outcomes, and in a 
future definitive trial we seek to incorporate these poten-
tial moderators into a process evaluation.64
Many participants’ accounts specifically highlight the 
novelty and value of MT in comparison to other treat-
ments, with participants appreciating the distinctive focus 
on allowing (as opposed to controlling) symptoms. These 
data support the potential of MT to offer patients a mean-
ingfully distinct alternative to other NICE-recommended 
treatments for current depression, thereby facilitating 
genuine patient choice as enshrined in the forthcoming 
NICE guidelines for depression.65 While our pilot trial 
results29 suggest that MT may be equivalent in effective-
ness to other psychological therapies, treatment effective-
ness varies at the level of the individual66 67: thus, while 
some participants who did not consider MT to be accept-
able may be better suited to one of the currently avail-
able NICE-recommended treatments for depression,9 
others may find MT more beneficial. Indeed, given the 
number of our participants who had tried other treat-
ments in the past, these findings provide some early and 
tentative insights into the possible value of MT for some 
patients who do not respond to NICE-recommended 
first-line psychological treatments. In the context of little 
evidence to guide the management of these patients68 
and an absence of a specific and effective treatment 
pathway within the NICE guidelines, it makes sense to 
test treatments which offer patients, for whom establish 
treatments have failed, a qualitatively different approach 
towards mental health.
The views of participants about MT may be of interest to 
clinicians and researchers more broadly. Although many 
have suggested that features of MT such as rest, Fumon 
(inattention to symptoms) and the concept of allowing 
rather than controlling symptoms may require dilution 
for a Western population,23 69–72 we have tested a version 
of MT which closely aligns with the original four-phased 
inpatient model21 by incorporating all such features. The 
views of many participants who valued not only MT but 
these specific features suggest that MT may not require as 
much modification to achieve cultural accommodation in 
the West as many authors have previously deemed neces-
sary, yet not empirically investigated.23 72–77
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